ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SYS6041

A development code. Also written as “SYS6041, bevacizumab”, “SYS6041, carboplatin, bevacizumab” and “SYS6041, enlonstobart, bevacizumab”.

Its studies are mostly in Ovarian Neoplasms, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Jul 8, 20262 company-led studies, 2 open or runningNext primary completion: Mar 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 2since Jul 8, 2026Jul 8, 2026Mar 28, 2027phase 2 · NCT07744763

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2026First studies: 2 phase 2 studiesFirst studyNCT07714668, NCT07744763

Ahead

  1. Mar 28, 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT07744763
  2. Apr 30, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT07714668

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07744763Advanced Solid Tumors · China2RecruitingMar 28, 2027260
NCT07714668Ovarian Neoplasms · China2RecruitingApr 30, 2028171

How it is read

Names in the registry

  • “SYS6041, bevacizumab”, 1 entry
  • “SYS6041, carboplatin, bevacizumab”, 1 entry
  • “SYS6041, enlonstobart, bevacizumab”, 1 entry
  • “SYS6041”, 1 entry

Codes read as this program: SYS6041.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
SYS6041 (CSPC Pharmaceutical Group): development program | ClinicalTrials.gg